| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Cecropin P1, porcine acetate targets the membranes of Gram-negative bacteria, where it exerts its antibacterial effect by disrupting membrane integrity. Its antiviral activity against PRRSV involves multiple mechanisms. It displays extracellular virucidal activity, directly inactivating the virus particles. Additionally, it exerts a potent inhibitory effect when added before, simultaneously with, or after viral inoculation, suggesting it can also interfere with viral entry or replication within the host cell. This multi-faceted antiviral mechanism makes it a particularly interesting candidate for combating viral infections.
|
|---|---|
| ln Vitro |
Cecropin P1, porcine (0-480 μg/mL, 36-96 h) significantly suppresses CH-1a infection and replication in Marc-145 cells [2]. In addition to exhibiting extracellular virucidal action against PRRSV (porcine reproductive and respiratory syndrome virus) at concentrations of 0-480 μg/mL for 36 hours, cecropin P1, porcine, also has a strong inhibitory impact when administered before to, concurrently with, or following viral inoculation[2]. In the latter stages of infection, cecropin P1, porcine (480 μg/mL, 0–72 h), inhibits the apoptosis caused by CH-1a[2]. Viral particle release is inhibited by cecropin P1, porcine (0-480 μg/mL, 0–4 h)[2].
In vitro, Cecropin P1 (0-480 µg/mL, 36-96 h) markedly inhibits CH-1a infection and replication in Marc-145 cells, with an EC50 of 112 µg/mL. It displays extracellular virucidal activity against PRRSV and exerts a potent inhibitory effect when added before, simultaneously with, or after viral inoculation. The compound also blocks CH-1a-induced apoptosis during the late phase of infection. Its antibacterial activity against Gram-negative bacteria has also been confirmed. The estimated CC50 (half-maximal cytotoxic concentration) for Marc-145 cells is 719 µg/mL, indicating a degree of selectivity for viral inhibition over host cell toxicity. |
| ln Vivo |
In rats suffering from septic shock, cecropin P1 (1 mg/kg, IP, once) inhibits the growth of bacteria, endotoxemia, and mortality[3].
In vivo, Cecropin P1 (1 mg/kg, IP, once) has been shown to prevent bacterial growth, endotoxemia, and mortality in a rat model of septic shock. This demonstrates its potential as a systemic antimicrobial agent in a clinically relevant infection model. While specific in vivo data for its antiviral activity are not detailed, its potent in vitro activity against PRRSV strongly suggests that it would have efficacy in pig models of PRRSV infection. Such studies would be essential for evaluating its potential as a veterinary therapeutic. |
| Enzyme Assay |
Non-cellular assays for Cecropin P1 are not typically performed as it is an antimicrobial peptide that functions through membrane disruption and antiviral mechanisms that require a cellular context. Its antibacterial activity is assessed using standard minimum inhibitory concentration (MIC) assays against bacterial cultures. Its virucidal activity can be assessed by incubating the peptide with virus particles and then measuring the remaining infectivity in a cell-based assay.
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: Marc-145 cells Tested Concentrations: 160, 320, and 480 μg/mL Incubation Duration: 36, 48, 72, 96 h Experimental Results: Dramatically inhibited viral infection in a dose-dependent manner at 36 h postinfection. Inhibited CH -1a infection in Marc-145 cells with a 50% effective concentration(EC50) of 112 μg/mL. The 50% cytotoxic concentration(CC50) of Cecropin P1 for Marc-145 cells was estimated to be 719 μg/mL. Western Blot Analysis[2] Cell Types: Marc-145 cells Tested Concentrations: 160, 320, and 480 μg/mL Incubation Duration: 36 h Experimental Results: Dramatically decreased the expression of the viral N protein when administered with either the pre-, co-, or posttreatment method. In vitro cellular assays are used to characterize the antiviral activity of Cecropin P1. Marc-145 cells, which are susceptible to PRRSV infection, are treated with the peptide at various concentrations (0-480 µg/mL) for defined periods (36-96 h). The extent of viral infection and replication is then measured by quantifying viral N protein expression via Western blotting or by determining viral titers. The compound's ability to inhibit viral entry, replication, or release can be determined by adding it at different time points relative to viral inoculation. Cell viability is assessed to determine the CC50 and selectivity index. |
| Animal Protocol |
In vivo animal experiments for Cecropin P1 have been conducted in a rat model of septic shock. In this model, the peptide is administered at a dose of 1 mg/kg via intraperitoneal (IP) injection, once. The primary endpoints are prevention of bacterial growth, reduction of endotoxemia, and improvement in survival. For studying its antiviral activity, the compound would likely be evaluated in a pig model of PRRSV infection, where it could be administered via various routes (e.g., intramuscular, subcutaneous) and its effect on viral load, clinical signs, and pathology would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties for Cecropin P1 are not detailed in the available sources. As a peptide with a molecular weight of 3398.91, its PK would be influenced by factors such as proteolytic degradation, renal clearance, and potential binding to plasma proteins. Peptides are typically administered via injection to avoid first-pass metabolism. The stability and half-life of Cecropin P1 in vivo would be key determinants of its dosing regimen. It is supplied as a powder and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cecropin P1 are limited. The estimated CC50 for Marc-145 cells is 719 µg/mL, indicating a moderate safety margin in vitro. In the rat model of septic shock, no overt toxicity was reported at the dose of 1 mg/kg. However, comprehensive toxicological studies, including acute and repeated-dose toxicity in relevant species (e.g., pigs), would be required to fully characterize its safety profile for potential therapeutic use. It is intended for research use only and not for human consumption.
|
| References |
|
| Additional Infomation |
Cecropin P1, porcine acetate has a molecular weight of 3398.91 and a sequence of SWLSKTAKKLENSAKKRISEGIAIAIQGGRR. It is an endogenous metabolite and an antimicrobial peptide with anti-infection activity. It is supplied for research purposes only. Its dual antibacterial and antiviral properties make it a valuable tool for studying host defense peptides and for the development of new strategies to combat bacterial and viral infections, particularly in the swine industry. It is not approved for clinical or veterinary use.
|
| Molecular Formula |
C₁₄₉H₂₅₇N₄₅O₄₅
|
|---|---|
| Molecular Weight |
3398.91
|
| Related CAS # |
Cecropin P1, porcine;125667-96-1
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2942 mL | 1.4711 mL | 2.9421 mL | |
| 5 mM | 0.0588 mL | 0.2942 mL | 0.5884 mL | |
| 10 mM | 0.0294 mL | 0.1471 mL | 0.2942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
